Long Zhi-Yong, Wu Jia-Min, Xiang Wang, Yuan Meng-Xia, Wu Yong-He, Li Jun, Yu Gan-Peng, Yang Tiejun
Department of Rehabilitation Medicine, Guangzhou Panyu Central Hospital, Guangzhou, China.
Hunan University of Chinese Medicine, Changsha, Hunan, China.
Evid Based Complement Alternat Med. 2022 Sep 22;2022:7017610. doi: 10.1155/2022/7017610. eCollection 2022.
Osteoporosis is an important health problem worldwide. Liuwei Dihuang Decoction (LDD) and its main ingredients may have a good clinical effect on osteoporosis. Meanwhile, its mechanism for treating osteoporosis needs to be further revealed in order to provide a basis for future drug development.
A systematic biological methodology was utilized to construct and analyze the LDD-osteoporosis network. After that, the human transcription data of LDD intervention in patients with osteoporosis and protein arrays data of LDD intervention in osteoporosis rats were collected. The human transcription data analysis, protein arrays data analysis, and molecular docking were performed to validate the findings of the prediction network (LDD-osteoporosis PPI network). Finally, animal experiments were conducted to verify the prediction results of systematic pharmacology.
(1) LDD-osteoporosis PPI network shows the potential compounds, potential targets (such as ALB, IGF1, SRC, and ESR1), clusters, biological processes (such as positive regulation of calmodulin 1-monooxygenase activity, estrogen metabolism, and endothelial cell proliferation), and signaling and Reactome pathways (such as JAK-STAT signaling pathway, osteoclast differentiation, and degradation of the extracellular matrix) of LDD intervention in osteoporosis. (2) Human transcriptomics data and protein arrays data validated the findings of the LDD-osteoporosis PPI network. (3) The animal experiments showed that LDD can improve bone mineral density (BMD), increase serum estradiol (E2) and alkaline phosphatase (ALP) levels, and upregulate Wnt3a and -catenin mRNA expression ( < 0.05). (4) Molecular docking results showed that alisol A, dioscin, loganin, oleanolic acid, pachymic acid, and ursolic acid may stably bind to JAK2, ESR1, and CTNNB1.
LDD may have a therapeutic effect on osteoporosis through regulating the targets (such as ALB, IGF1, SRC, and ESR1), biological processes (such as positive regulation of calmodulin 1-monooxygenase activity, estrogen metabolism, and endothelial cell proliferation), and pathways (such as JAK-STAT signaling pathway, osteoclast differentiation, and degradation of the extracellular matrix) found in this research.
骨质疏松症是全球范围内一个重要的健康问题。六味地黄丸(LDD)及其主要成分可能对骨质疏松症具有良好的临床疗效。同时,其治疗骨质疏松症的机制有待进一步揭示,以便为未来的药物研发提供依据。
运用系统生物学方法构建并分析LDD-骨质疏松症网络。之后,收集LDD干预骨质疏松症患者的人类转录组数据以及LDD干预骨质疏松症大鼠的蛋白质芯片数据。进行人类转录组数据分析、蛋白质芯片数据分析以及分子对接,以验证预测网络(LDD-骨质疏松症蛋白质-蛋白质相互作用网络)的研究结果。最后,开展动物实验以验证系统药理学的预测结果。
(1)LDD-骨质疏松症蛋白质-蛋白质相互作用网络显示了LDD干预骨质疏松症的潜在化合物、潜在靶点(如ALB、IGF1、SRC和ESR1)、聚类、生物学过程(如钙调蛋白1-单加氧酶活性的正调控、雌激素代谢和内皮细胞增殖)以及信号通路和Reactome通路(如JAK-STAT信号通路、破骨细胞分化和细胞外基质降解)。(2)人类转录组学数据和蛋白质芯片数据验证了LDD-骨质疏松症蛋白质-蛋白质相互作用网络的研究结果。(3)动物实验表明,LDD可提高骨密度(BMD),增加血清雌二醇(E2)和碱性磷酸酶(ALP)水平,并上调Wnt3a和β-连环蛋白mRNA表达(P<0.05)。(4)分子对接结果表明,泽泻醇A、薯蓣皂苷、马钱子苷、齐墩果酸、茯苓酸和熊果酸可能与JAK2、ESR1和CTNNB1稳定结合。
LDD可能通过调节本研究中发现的靶点(如ALB、IGF1、SRC和ESR1)、生物学过程(如钙调蛋白1-单加氧酶活性的正调控、雌激素代谢和内皮细胞增殖)以及通路(如JAK-STAT信号通路、破骨细胞分化和细胞外基质降解)对骨质疏松症具有治疗作用。